A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis

C. A. Whipple, A. L. Young, Murray Korc

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinomas (PDACs) exhibit multiple molecular alterations and overexpress heparin-binding growth factors (HBGFs) and glypican-1 (GPC1), a heparan sulfate proteoglycan that promotes efficient signaling by HBGFs. It is not known, however, whether GPC1 has a role in genetic mouse models of PDAC. Therefore, we generated a GPC1 null mouse that combines pancreas-specific Cre-mediated activation of oncogenic Kras (Kras G12D) with deletion of a conditional INK4A/Arf allele (Pdx1-Cre;LSL-KrasG12D;INK4A/Arflox/lox;GPC1 -/- mice). By comparison with Pdx1-Cre;LSL-KrasG12D;INK4A/ Arflox/lox mice that were wild type for GPC1, the Pdx1-Cre;LSL-KrasG12D;INK4A/Arflox/lox;GPC1-/- mice exhibited attenuated pancreatic tumor growth and invasiveness, decreased cancer cell proliferation and mitogen-activated protein kinase activation. These mice also exhibited suppressed angiogenesis in conjunction with decreased expression of messenger RNAs encoding several pro-angiogenic factors and molecules, including vascular endothelial growth factor-A (VEGF-A), SRY-box containing gene (SOX17), chemokine C-X3-C motif ligand 1 (CX3CL1) and integrin Β3 (ITGB3). Moreover, pancreatic cancer cells isolated from the tumors of GPC1-/- mice were not as invasive in response to fibroblast growth factor-2 (FGF-2) as cancer cells isolated from wild-type mice, and formed smaller tumors that exhibited an attenuated metastatic potential. Similarly, VEGF-A and FGF-2 did not enhance the migration of hepatic endothelial cells and immortalized murine embryonic fibroblasts isolated from GPC1 null mice. These data demonstrate in an oncogenic Kras-driven genetic mouse model of PDAC that tumor growth, angiogenesis and invasion are enhanced by GPC1, and suggest that suppression of GPC1 may be an important component of therapeutic strategies in PDAC.

Original languageEnglish (US)
Pages (from-to)2535-2544
Number of pages10
JournalOncogene
Volume31
Issue number20
DOIs
StatePublished - May 17 2012
Externally publishedYes

Fingerprint

Glypicans
Genetic Models
Pancreatic Neoplasms
Adenocarcinoma
Neoplasms
Fibroblast Growth Factor 2
Vascular Endothelial Growth Factor A
Heparin
Intercellular Signaling Peptides and Proteins
Chemokine CX3CL1
Heparan Sulfate Proteoglycans
Angiogenesis Inducing Agents
Growth
Mitogen-Activated Protein Kinases
Integrins
Pancreas
Hepatocytes
Endothelial Cells
Fibroblasts

Keywords

  • angiogenesis
  • glypican-1
  • pancreatic cancer
  • proliferation
  • tumor microenvironment

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. / Whipple, C. A.; Young, A. L.; Korc, Murray.

In: Oncogene, Vol. 31, No. 20, 17.05.2012, p. 2535-2544.

Research output: Contribution to journalArticle

Whipple, C. A. ; Young, A. L. ; Korc, Murray. / A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. In: Oncogene. 2012 ; Vol. 31, No. 20. pp. 2535-2544.
@article{825d1f42510d479e942dbbba092f17c0,
title = "A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis",
abstract = "Pancreatic ductal adenocarcinomas (PDACs) exhibit multiple molecular alterations and overexpress heparin-binding growth factors (HBGFs) and glypican-1 (GPC1), a heparan sulfate proteoglycan that promotes efficient signaling by HBGFs. It is not known, however, whether GPC1 has a role in genetic mouse models of PDAC. Therefore, we generated a GPC1 null mouse that combines pancreas-specific Cre-mediated activation of oncogenic Kras (Kras G12D) with deletion of a conditional INK4A/Arf allele (Pdx1-Cre;LSL-KrasG12D;INK4A/Arflox/lox;GPC1 -/- mice). By comparison with Pdx1-Cre;LSL-KrasG12D;INK4A/ Arflox/lox mice that were wild type for GPC1, the Pdx1-Cre;LSL-KrasG12D;INK4A/Arflox/lox;GPC1-/- mice exhibited attenuated pancreatic tumor growth and invasiveness, decreased cancer cell proliferation and mitogen-activated protein kinase activation. These mice also exhibited suppressed angiogenesis in conjunction with decreased expression of messenger RNAs encoding several pro-angiogenic factors and molecules, including vascular endothelial growth factor-A (VEGF-A), SRY-box containing gene (SOX17), chemokine C-X3-C motif ligand 1 (CX3CL1) and integrin Β3 (ITGB3). Moreover, pancreatic cancer cells isolated from the tumors of GPC1-/- mice were not as invasive in response to fibroblast growth factor-2 (FGF-2) as cancer cells isolated from wild-type mice, and formed smaller tumors that exhibited an attenuated metastatic potential. Similarly, VEGF-A and FGF-2 did not enhance the migration of hepatic endothelial cells and immortalized murine embryonic fibroblasts isolated from GPC1 null mice. These data demonstrate in an oncogenic Kras-driven genetic mouse model of PDAC that tumor growth, angiogenesis and invasion are enhanced by GPC1, and suggest that suppression of GPC1 may be an important component of therapeutic strategies in PDAC.",
keywords = "angiogenesis, glypican-1, pancreatic cancer, proliferation, tumor microenvironment",
author = "Whipple, {C. A.} and Young, {A. L.} and Murray Korc",
year = "2012",
month = "5",
day = "17",
doi = "10.1038/onc.2011.430",
language = "English (US)",
volume = "31",
pages = "2535--2544",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "20",

}

TY - JOUR

T1 - A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis

AU - Whipple, C. A.

AU - Young, A. L.

AU - Korc, Murray

PY - 2012/5/17

Y1 - 2012/5/17

N2 - Pancreatic ductal adenocarcinomas (PDACs) exhibit multiple molecular alterations and overexpress heparin-binding growth factors (HBGFs) and glypican-1 (GPC1), a heparan sulfate proteoglycan that promotes efficient signaling by HBGFs. It is not known, however, whether GPC1 has a role in genetic mouse models of PDAC. Therefore, we generated a GPC1 null mouse that combines pancreas-specific Cre-mediated activation of oncogenic Kras (Kras G12D) with deletion of a conditional INK4A/Arf allele (Pdx1-Cre;LSL-KrasG12D;INK4A/Arflox/lox;GPC1 -/- mice). By comparison with Pdx1-Cre;LSL-KrasG12D;INK4A/ Arflox/lox mice that were wild type for GPC1, the Pdx1-Cre;LSL-KrasG12D;INK4A/Arflox/lox;GPC1-/- mice exhibited attenuated pancreatic tumor growth and invasiveness, decreased cancer cell proliferation and mitogen-activated protein kinase activation. These mice also exhibited suppressed angiogenesis in conjunction with decreased expression of messenger RNAs encoding several pro-angiogenic factors and molecules, including vascular endothelial growth factor-A (VEGF-A), SRY-box containing gene (SOX17), chemokine C-X3-C motif ligand 1 (CX3CL1) and integrin Β3 (ITGB3). Moreover, pancreatic cancer cells isolated from the tumors of GPC1-/- mice were not as invasive in response to fibroblast growth factor-2 (FGF-2) as cancer cells isolated from wild-type mice, and formed smaller tumors that exhibited an attenuated metastatic potential. Similarly, VEGF-A and FGF-2 did not enhance the migration of hepatic endothelial cells and immortalized murine embryonic fibroblasts isolated from GPC1 null mice. These data demonstrate in an oncogenic Kras-driven genetic mouse model of PDAC that tumor growth, angiogenesis and invasion are enhanced by GPC1, and suggest that suppression of GPC1 may be an important component of therapeutic strategies in PDAC.

AB - Pancreatic ductal adenocarcinomas (PDACs) exhibit multiple molecular alterations and overexpress heparin-binding growth factors (HBGFs) and glypican-1 (GPC1), a heparan sulfate proteoglycan that promotes efficient signaling by HBGFs. It is not known, however, whether GPC1 has a role in genetic mouse models of PDAC. Therefore, we generated a GPC1 null mouse that combines pancreas-specific Cre-mediated activation of oncogenic Kras (Kras G12D) with deletion of a conditional INK4A/Arf allele (Pdx1-Cre;LSL-KrasG12D;INK4A/Arflox/lox;GPC1 -/- mice). By comparison with Pdx1-Cre;LSL-KrasG12D;INK4A/ Arflox/lox mice that were wild type for GPC1, the Pdx1-Cre;LSL-KrasG12D;INK4A/Arflox/lox;GPC1-/- mice exhibited attenuated pancreatic tumor growth and invasiveness, decreased cancer cell proliferation and mitogen-activated protein kinase activation. These mice also exhibited suppressed angiogenesis in conjunction with decreased expression of messenger RNAs encoding several pro-angiogenic factors and molecules, including vascular endothelial growth factor-A (VEGF-A), SRY-box containing gene (SOX17), chemokine C-X3-C motif ligand 1 (CX3CL1) and integrin Β3 (ITGB3). Moreover, pancreatic cancer cells isolated from the tumors of GPC1-/- mice were not as invasive in response to fibroblast growth factor-2 (FGF-2) as cancer cells isolated from wild-type mice, and formed smaller tumors that exhibited an attenuated metastatic potential. Similarly, VEGF-A and FGF-2 did not enhance the migration of hepatic endothelial cells and immortalized murine embryonic fibroblasts isolated from GPC1 null mice. These data demonstrate in an oncogenic Kras-driven genetic mouse model of PDAC that tumor growth, angiogenesis and invasion are enhanced by GPC1, and suggest that suppression of GPC1 may be an important component of therapeutic strategies in PDAC.

KW - angiogenesis

KW - glypican-1

KW - pancreatic cancer

KW - proliferation

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=84861373535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861373535&partnerID=8YFLogxK

U2 - 10.1038/onc.2011.430

DO - 10.1038/onc.2011.430

M3 - Article

VL - 31

SP - 2535

EP - 2544

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 20

ER -